Tazemetostat (** Tazverik® (brand name); tazemetostat (generic name) **)
Other Medications
Description
Tazemetostat is a medication being studied in clinical trials for certain types of cancer. In colorectal cancer, it has been investigated in trials specifically for patients whose tumors are MSI-H (microsatellite instability-high) or MMR-deficient (mismatch repair deficient). These are specific genetic characteristics of some colorectal cancers. The drug is being studied in combination with durvalumab, a type of immunotherapy, to see if this combination is effective. The trial design involves multiple cancer types being studied at the same time, including colorectal cancer.
Mechanism of Action
Tazemetostat targets a specific protein involved in gene regulation within cancer cells. By inhibiting this protein, tazemetostat aims to disrupt the processes that allow cancer cells to grow and survive. In the context of MSI-H/MMR-deficient cancers, this approach is being explored as a potential way to make the cancer more sensitive to immunotherapy or to directly inhibit tumor growth.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.